230 related articles for article (PubMed ID: 26417039)
1. Outpatient Intraperitoneal Catumaxomab Therapy for Malignant Ascites Related to Advanced Gynecologic Neoplasms.
Kurbacher CM; Horn O; Kurbacher JA; Herz S; Kurbacher AT; Hildenbrand R; Bollmann R
Oncologist; 2015 Nov; 20(11):1333-41. PubMed ID: 26417039
[TBL] [Abstract][Full Text] [Related]
2. Catumaxomab--trifunctional anti-EpCAM antibody used to treat malignant ascites.
Bokemeyer C
Expert Opin Biol Ther; 2010 Aug; 10(8):1259-69. PubMed ID: 20624115
[TBL] [Abstract][Full Text] [Related]
3. Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study.
Sehouli J; Pietzner K; Wimberger P; Vergote I; Rosenberg P; Schneeweiss A; Bokemeyer C; Salat C; Scambia G; Berton-Rigaud D; Santoro A; Cervantes A; Trédan O; Tournigand C; Colombo N; Dudnichenko AS; Westermann A; Friccius-Quecke H; Lordick F
Med Oncol; 2014 Aug; 31(8):76. PubMed ID: 24965536
[TBL] [Abstract][Full Text] [Related]
4. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study.
Burges A; Wimberger P; Kümper C; Gorbounova V; Sommer H; Schmalfeldt B; Pfisterer J; Lichinitser M; Makhson A; Moiseyenko V; Lahr A; Schulze E; Jäger M; Ströhlein MA; Heiss MM; Gottwald T; Lindhofer H; Kimmig R
Clin Cancer Res; 2007 Jul; 13(13):3899-905. PubMed ID: 17606723
[TBL] [Abstract][Full Text] [Related]
5. Catumaxomab: malignant ascites: unjustified marketing authorisation.
Prescrire Int; 2010 Oct; 19(109):207-9. PubMed ID: 21180374
[TBL] [Abstract][Full Text] [Related]
6. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial.
Heiss MM; Murawa P; Koralewski P; Kutarska E; Kolesnik OO; Ivanchenko VV; Dudnichenko AS; Aleknaviciene B; Razbadauskas A; Gore M; Ganea-Motan E; Ciuleanu T; Wimberger P; Schmittel A; Schmalfeldt B; Burges A; Bokemeyer C; Lindhofer H; Lahr A; Parsons SL
Int J Cancer; 2010 Nov; 127(9):2209-21. PubMed ID: 20473913
[TBL] [Abstract][Full Text] [Related]
7. Detection of soluble EpCAM (sEpCAM) in malignant ascites predicts poor overall survival in patients treated with catumaxomab.
Seeber A; Braicu I; Untergasser G; Nassir M; Fong D; Botta L; Gastl G; Fiegl H; Zeimet A; Sehouli J; Spizzo G
Oncotarget; 2015 Sep; 6(28):25017-23. PubMed ID: 26296970
[TBL] [Abstract][Full Text] [Related]
8. Regression of liver metastases after treatment with intraperitoneal catumaxomab for malignant ascites due to breast cancer.
Petrelli F; Borgonovo K; Lonati V; Elia S; Barni S
Target Oncol; 2013 Dec; 8(4):291-4. PubMed ID: 23197249
[TBL] [Abstract][Full Text] [Related]
9. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy.
Seimetz D; Lindhofer H; Bokemeyer C
Cancer Treat Rev; 2010 Oct; 36(6):458-67. PubMed ID: 20347527
[TBL] [Abstract][Full Text] [Related]
10. Re-challenge with catumaxomab in patients with malignant ascites: results from the SECIMAS study.
Pietzner K; Vergote I; Santoro A; Chekerov R; Marmé F; Rosenberg P; Martinius H; Friccius-Quecke H; Sehouli J
Med Oncol; 2014 Dec; 31(12):308. PubMed ID: 25367854
[TBL] [Abstract][Full Text] [Related]
11. Dramatic Response to Catumaxomab Treatment for Malign Ascites Related to Renal Cell Carcinoma With Sarcomotoid Differentiation.
Pilanc KN; Ordu Ç; Akpnar H; Balc C; Başsülü N; Köksal Üİ; Elbüken F; Okutur K; Bülbül G; Sağlam S; Demir G
Am J Ther; 2016; 23(4):e1078-81. PubMed ID: 24732906
[TBL] [Abstract][Full Text] [Related]
12. Intraperitoneal catumaxomab therapy in a cirrhotic patient with malignant ascites due to urethelial carcinoma: a case report.
Krawczyk M; Zimmermann S; Vidacek D; Lammert F
Onkologie; 2012; 35(10):592-4. PubMed ID: 23038231
[TBL] [Abstract][Full Text] [Related]
13. Catumaxomab: in malignant ascites.
Frampton JE
Drugs; 2012 Jul; 72(10):1399-410. PubMed ID: 22676343
[TBL] [Abstract][Full Text] [Related]
14. A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3.
Mau-Sørensen M; Dittrich C; Dienstmann R; Lassen U; Büchler W; Martinius H; Tabernero J
Cancer Chemother Pharmacol; 2015 May; 75(5):1065-73. PubMed ID: 25814216
[TBL] [Abstract][Full Text] [Related]
15. Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study.
Berek JS; Edwards RP; Parker LP; DeMars LR; Herzog TJ; Lentz SS; Morris RT; Akerley WL; Holloway RW; Method MW; Plaxe SC; Walker JL; Friccius-Quecke H; Krasner CN
Int J Gynecol Cancer; 2014 Nov; 24(9):1583-9. PubMed ID: 25254563
[TBL] [Abstract][Full Text] [Related]
16. The trifunctional antibody catumaxomab in treatment of malignant ascites and peritoneal carcinomatosis.
Ströhlein MA; Heiss MM
Future Oncol; 2010 Sep; 6(9):1387-94. PubMed ID: 20919824
[TBL] [Abstract][Full Text] [Related]
17. The contribution of catumaxomab in the treatment of malignant ascites in patients with ovarian cancer: a review of the literature.
Tsikouras P; Tsagias N; Pinidis P; Csorba R; Vrachnis N; Dafopoulos A; Bouchlariotou S; Liberis A; Teichmann AT; von Tempelhoff GF
Arch Gynecol Obstet; 2013 Sep; 288(3):581-5. PubMed ID: 23644922
[TBL] [Abstract][Full Text] [Related]
18. Catumaxomab: a bispecific trifunctional antibody.
Sebastian M; Kuemmel A; Schmidt M; Schmittel A
Drugs Today (Barc); 2009 Aug; 45(8):589-97. PubMed ID: 19927225
[TBL] [Abstract][Full Text] [Related]
19. Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study.
Sebastian M; Passlick B; Friccius-Quecke H; Jäger M; Lindhofer H; Kanniess F; Wiewrodt R; Thiel E; Buhl R; Schmittel A
Cancer Immunol Immunother; 2007 Oct; 56(10):1637-44. PubMed ID: 17410361
[TBL] [Abstract][Full Text] [Related]
20. Immunological changes in the ascites of cancer patients after intraperitoneal administration of the bispecific antibody catumaxomab (anti-EpCAM×anti-CD3).
Fossati M; Buzzonetti A; Monego G; Catzola V; Scambia G; Fattorossi A; Battaglia A
Gynecol Oncol; 2015 Aug; 138(2):343-51. PubMed ID: 26049121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
